XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
  Breast
  Skin
  Blood
  Prostate
  Liver
  Colon
  Thyroid
  Endometrial
  Brain
  Therapy
  Risk Factors
  Esophageal
  Bladder
  Lung
  Rectal Cancer
  Pancreatic Cancer
  Bone Cancer
  Cervical Cancer
  Testicular Cancer
  Gastric Cancer
  Ovarian Cancer
  Nerve Tissue
  Renal Cell Carcinoma
 Psychiatry
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
 Cardiology
 Obstetrics
 Infectious Diseases
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
Search

Last Updated: Nov 17th, 2006 - 22:35:04

Rectal Cancer Channel
subscribe to Rectal Cancer newsletter

Latest Research : Cancer : Rectal Cancer

   DISCUSS   |   EMAIL   |   PRINT
TNFerade(TM) to Continue in Phase II Trial
May 25, 2005, 20:52, Reviewed by: Dr.

"Our clinical results to date with TNFerade(TM) in a variety of solid tumors, including pancreatic and rectal cancer, have been very encouraging and we look forward to expanding our efforts in rectal cancer."

 
GenVec, Inc. (Nasdaq:GNVC) announced today that the U.S. Food and Drug Administration (FDA) informed the company that it may resume its Phase II clinical trial of TNFerade(TM) in rectal cancer. This trial will be conducted in collaboration with the Surgery Branch of the National Cancer Institute to evaluate the use of TNFerade in combination with chemoradiation for rectal cancer to improve complete response rates, surgical outcomes and survival.

The FDA indicated that the clinical hold issues have been satisfactorily addressed for the rectal and esophageal indications and, as such, the clinical hold has been removed from the TNFerade(TM) IND. GenVec will resume the enrollment process for the Phase II rectal study. For the esophageal study, the patient accrual is now completed and closed. Follow-up of the patients in the esophageal study is ongoing.

"We are pleased to resume clinical testing of TNFerade(TM) for the treatment of rectal cancer and greatly appreciate the FDA's efforts to resolve the clinical hold on this program," said Dr. Paul H. Fischer, President and CEO of GenVec. "Our clinical results to date with TNFerade(TM) in a variety of solid tumors, including pancreatic and rectal cancer, have been very encouraging and we look forward to expanding our efforts in rectal cancer."
 

- U.S. Food and Drug Administration (FDA)
 

www.genvec.com

 
Subscribe to Rectal Cancer Newsletter
E-mail Address:

 

The company will highlight the TNFerade(TM) program during a corporate presentation on Thursday, May 26, 2005 at 1:00 pm ET at the Fourth Annual Needham & Company Biotechnology Conference. The presentation will be webcast live on GenVec's website at www.genvec.com under "Webcasts and Data."

GenVec, Inc. is a clinical stage biopharmaceutical company developing TNFerade(TM) for cancer as well as BIOBYPASS(R) for severe coronary artery disease and AdPEDF for age-related macular degeneration. Additional information on GenVec is available at www.genvec.com and in the company's various filings with the Securities and Exchange Commission.

Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding future programs and studies, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. GenVec cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks relating to the early stage of GenVec's product candidates under development; uncertainties relating to clinical trials; the timing and content of future U.S. Food and Drug Administration regulatory actions with respect to GenVec, its product candidates, or collaborators, risks relating to the commercialization, if any, of GenVec's proposed product candidates (such as marketing, regulatory, patent, product liability, supply, competition and other risks); dependence on the efforts of third parties; dependence on intellectual property; and risks that we may lack the financial resources and access to capital to fund our operations. Further information on the factors and risks that could affect GenVec's business, financial conditions and results of operations, are contained in GenVec's filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. These forward-looking statements speak only as of the date of this press release, and GenVec assumes no duty to update forward-looking statements.

Contacts


GenVec, Inc.
Rena Cohen, 240-632-5501
[email protected]


Related Rectal Cancer News

TNFerade(TM) to Continue in Phase II Trial
Radiotherapy for Prostate Cancer Doubles risk for Rectal Cancer


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us